NR1H4 and metabolic dysfunction-associated steatohepatitis: Furthermore, in a phase 2, double-blind, randomized, placebo-controlled, multicenter study (NCT02633956) that evaluated the effect of Obeticholic acid (OCA, a synthetic bile acid (BA), and farnesoid X receptor (FXR) agonist), and the subsequent addition of Atorvastatin therapy, on lipoprotein metabolism in subjects with NASH (fibrosis stages 1–4), OCA-induced increases in LDL-C in patients were mitigated with Atorvastatin.120